Advertisement

Urine pp 75-82 | Cite as

Urine Glucose Levels Are Disordered Before Blood Glucose Level Increase Was Observed in Zucker Diabetic Fatty Rats

  • Wei Yin
  • Weiwei Qin
Chapter

Abstract

Many patients with diabetes are not diagnosed at all or are diagnosed too late to be effectively treated, resulting in nonspecific symptoms and a long period of incubation of the disease. Pre-diabetes is an early warning signal of diabetes, and the change of urine glucose in this period has been ignored even though urine has long been related with diabetes. In this study, Zucker diabetic fatty (ZDF) rats were used to test if there were changes in urine glucose before blood glucose increases. Six 8-week-old male ZDF rats (fa/fa) and Zucker lean (ZL) rats (fa/+) were fed with Purina 5008 high-fat diet and tested for fasting blood glucose and urine glucose. After 12 weeks of feeding, the urine glucose values of the ZL rats were normal (0–10 mmol/L), but the values of the ZDF model rats increased 10 weeks before their blood glucose levels elevated. The urine glucose values of the ZDF model rats showed a state of disorder that was frequently elevated (>10 mmol/L) and occasionally normal (0–10 mmol/L). This finding may provide an easy early screening for diabetes by long-term monitoring of urine glucose levels: pre-diabetes may be revealed by frequently disordered urine glucose levels over a period.

Keywords

Type 2 diabetes mellitus Urine glucose ZDF rats Impaired glucose regulation Prediabetes 

Notes

Acknowledgments

This chapter was modified from a paper reported by the author in Science China Life Sciences (Yin et al. 2018). The related contents are reused with permission.

References

  1. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:7539–53.Google Scholar
  2. American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016;39:S16.CrossRefGoogle Scholar
  3. Bansal N. Prediabetes diagnosis and treatment: a review. World J Diabetes. 2015;6:296.CrossRefGoogle Scholar
  4. Danaei G, Lu Y, Singh GM, Carnahan E, Stevens GA, Cowan MJ, Farzadfar F, Lin JK, Finucane MM, Rao M, et al. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2:634–47.CrossRefGoogle Scholar
  5. Hempe J, Elvert R, Schmidts HL, Kramer W, Herling AW. Appropriateness of the zucker diabetic fatty rat as a model for diabetic microvascular late complications. Lab Anim. 2012;46:32–9.CrossRefGoogle Scholar
  6. Khunti K, Mani H, Achana F, Cooper N, Gray LJ, Davies MJ. Systematic review and meta-analysis of response rates and diagnostic yield of screening for type 2 diabetes and those at high risk of diabetes. PLoS One. 2015;10:e0135702.CrossRefGoogle Scholar
  7. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du FY, Liu Y, Xu J, Conway B, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7:e30555.CrossRefGoogle Scholar
  8. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metabol. 2013a;98:E867–71.CrossRefGoogle Scholar
  9. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion. Diabetes Care. 2013b;36:2154–61.CrossRefGoogle Scholar
  10. Poretsky L. Principles of diabetes mellitus. JAMA. 2010;304:1615–6.Google Scholar
  11. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. PharmacoEconomics. 2015;33:811–31.CrossRefGoogle Scholar
  12. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012;380:1741–8.CrossRefGoogle Scholar
  13. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279–90.CrossRefGoogle Scholar
  14. Webb DR, Gray LJ, Khunti K, et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia. 2011;54:2237–46.CrossRefGoogle Scholar
  15. World Health Organization. Diabetes mellitus: report of a WHO study group., Technical report series. 727. Geneva: WHO; 1985.Google Scholar
  16. World Health Organization. Global report on diabetes. Geneva; 2016. Available from: http://apps.who.int/iris/handle/10665/204871.
  17. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang T, Jiang Y, Dai M, Lu J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–59.CrossRefGoogle Scholar
  18. Yang WY, Zhao WH, Xiao JZ, Li R, Zhang P, Kissimova-Skarbek K, Schneider E, Jia WP, Ji LN, Guo XH, et al. Medical care and payment for diabetes in China: enormous threat and great opportunity. PLoS One. 2012;7:e39513.CrossRefGoogle Scholar
  19. Yin W, Qin W, Gao Y. Urine glucose levels are disordered before blood glucose level increase was observed in Zucker diabetic fatty rats. Sci China Life Sci. 2018;61(7):844–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Wei Yin
    • 1
  • Weiwei Qin
    • 2
  1. 1.Biological Sample Analysis CenterGuangzhou General Pharmaceutical Research Institute Co., Ltd.GuangzhouChina
  2. 2.Department of Anesthesiology, Qingdao Municipal HospitalQingdao UniversityGuangzhouChina

Personalised recommendations